WO2003079981A3 - Bioadhesive drug delivery system - Google Patents

Bioadhesive drug delivery system Download PDF

Info

Publication number
WO2003079981A3
WO2003079981A3 PCT/US2003/008266 US0308266W WO03079981A3 WO 2003079981 A3 WO2003079981 A3 WO 2003079981A3 US 0308266 W US0308266 W US 0308266W WO 03079981 A3 WO03079981 A3 WO 03079981A3
Authority
WO
WIPO (PCT)
Prior art keywords
delivery system
drug delivery
phase
vaginal
essentially
Prior art date
Application number
PCT/US2003/008266
Other languages
French (fr)
Other versions
WO2003079981A2 (en
Inventor
Mitchell I Kirschner
R Saul Levinson
Thomas C Riley
Marc S Hermelin
Original Assignee
Drugtech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22282669&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2003079981(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Drugtech Corp filed Critical Drugtech Corp
Priority to EP03714226A priority Critical patent/EP1494630A4/en
Priority to AU2003218233A priority patent/AU2003218233A1/en
Publication of WO2003079981A2 publication Critical patent/WO2003079981A2/en
Publication of WO2003079981A3 publication Critical patent/WO2003079981A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention relates to a novel essentially pH neutral vaginal drug delivery system suitable for modified delivery of a therapeutically active material in the vaginal cavity. The vaginal drug delivery system comprises an essentially pH neutral emulsion having globules having two phases, an internal water soluble phase and an external water-insoluble phase or film, wherein the water-soluble interior phase contains a therapeutically active drug or drugs. One novel aspect of the vaginal drug delivery system is that the internal water soluble phase comprises an acidic buffered phase.
PCT/US2003/008266 2002-03-20 2003-03-19 Bioadhesive drug delivery system WO2003079981A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP03714226A EP1494630A4 (en) 2002-03-20 2003-03-19 Bioadhesive drug delivery system
AU2003218233A AU2003218233A1 (en) 2002-03-20 2003-03-19 Bioadhesive drug delivery system

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/101,014 US6899890B2 (en) 2002-03-20 2002-03-20 Bioadhesive drug delivery system
US10/101,014 2002-03-20

Publications (2)

Publication Number Publication Date
WO2003079981A2 WO2003079981A2 (en) 2003-10-02
WO2003079981A3 true WO2003079981A3 (en) 2003-11-06

Family

ID=22282669

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/008266 WO2003079981A2 (en) 2002-03-20 2003-03-19 Bioadhesive drug delivery system

Country Status (17)

Country Link
US (1) US6899890B2 (en)
EP (1) EP1494630A4 (en)
JP (1) JP4462818B2 (en)
KR (2) KR20030076159A (en)
CN (3) CN101045034A (en)
AR (1) AR039037A1 (en)
AU (2) AU2002300175B2 (en)
BR (1) BR0202767A (en)
CA (1) CA2392473C (en)
FR (1) FR2837389A1 (en)
HU (1) HUP0203102A3 (en)
IT (1) ITMI20021660A1 (en)
MX (1) MXPA02006943A (en)
PT (1) PT102854B (en)
RU (1) RU2320322C2 (en)
WO (1) WO2003079981A2 (en)
ZA (1) ZA200407535B (en)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060189552A1 (en) * 2000-12-12 2006-08-24 Mohan Vishnupad Dispenser for dispensing three or more actives
US7060732B2 (en) * 2000-12-12 2006-06-13 Imaginative Research Associates, Inc. Antibiotic/benzoyl peroxide dispenser
US6899890B2 (en) * 2002-03-20 2005-05-31 Kv Pharmaceutical Company Bioadhesive drug delivery system
US20060083759A1 (en) * 2002-07-17 2006-04-20 Aleksander Resman Stabilization of the profile of release of active substances from a formulation
WO2004105662A1 (en) * 2003-05-23 2004-12-09 Program For Appropriate Technology In Health Microbicidal compositions and methods of use
ITTO20030404A1 (en) * 2003-05-30 2004-11-30 Rottapharm S R L COMPOSITION FOR THE RESTORATION OF THE VAGINAL ECOSYSTEM
GB0315671D0 (en) * 2003-07-04 2003-08-13 Chelsea And Westminster Nhs Tr Improvements in or relating to organic compounds
JP2007505927A (en) 2003-09-19 2007-03-15 ドラッグテック コーポレイション Drug delivery system
US20060140990A1 (en) 2003-09-19 2006-06-29 Drugtech Corporation Composition for topical treatment of mixed vaginal infections
EA010885B1 (en) 2003-12-08 2008-12-30 Бентли Фармасьютикалз, Инк. Pharmaceutical compositions and methods for insulin treatment
US8057433B2 (en) 2004-07-08 2011-11-15 Drugtech Corporation Delivery system
UA93354C2 (en) * 2004-07-09 2011-02-10 Гилиад Сайенсиз, Инк. Topical antiviral formulations
US20060093675A1 (en) * 2004-10-29 2006-05-04 Mathew Ebmeier Intravaginal treatment of vaginal infections with metronidazole compositions
US7619008B2 (en) * 2004-11-12 2009-11-17 Kimberly-Clark Worldwide, Inc. Xylitol for treatment of vaginal infections
US20060217443A1 (en) * 2005-03-28 2006-09-28 Kimberly-Clark Worldwide, Inc. Method for preventing and/or treating vaginal and vulval infections
US20080193428A1 (en) 2005-04-27 2008-08-14 Shenzhen Phlora Biotechnology Limited Composition and Method for Modulating and Maintaining Vaginal Bacterial Flora and Vaginal Acidity
WO2006121429A1 (en) * 2005-05-06 2006-11-16 Imaginative Research Associates, Inc. Clindamycin compositions and delivery system therefor
CA2605341A1 (en) * 2005-05-09 2006-11-16 Drugtech Corporation Modified-release pharmaceutical compositions
US7786176B2 (en) * 2005-07-29 2010-08-31 Kimberly-Clark Worldwide, Inc. Vaginal treatment composition containing xylitol
DK1933810T3 (en) 2005-08-11 2013-01-28 Childrens Medical Center Intravesical drug delivery device and method
KR20080033400A (en) * 2005-08-12 2008-04-16 드러그테크 코포레이션 Estrogen compositions and therapeutic methods of use thereof
WO2007079391A2 (en) * 2006-01-05 2007-07-12 Drugtech Corporation Drug delivery system for bioadhesion to a vulvovaginal surface
JP2009522360A (en) * 2006-01-05 2009-06-11 ドラッグテック コーポレイション Composition and method of use thereof
JP2009526064A (en) * 2006-02-09 2009-07-16 シェーリング コーポレイション Pharmaceutical formulation
EP1872775A1 (en) * 2006-06-29 2008-01-02 Polichem S.A. Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant for the manufacture of a medicament for treating female genital disorders
WO2008005783A2 (en) * 2006-06-30 2008-01-10 Drugtech Corporation Treatment of non- infectious inflammatory vulvovaginitis with a bioadhesive clindamycin composition
US20080085877A1 (en) * 2006-08-10 2008-04-10 Drugtech Corporation Therapeutic methods of using estrogen compositions
US20080268022A1 (en) * 2007-02-23 2008-10-30 Mccabe R Tyler Mehtods for treating and preventing ailments caused by human papillomavirus
US20080287408A1 (en) * 2007-05-14 2008-11-20 Drugtech Corporation Endometriosis treatment
EP1994938A1 (en) * 2007-05-21 2008-11-26 Combinature Biopharm AG New lipoglycodepsipeptide compositions
BRPI0820800B8 (en) 2007-12-11 2021-06-22 Massachusetts Inst Technology implantable medical device for controlled drug release
US20090238867A1 (en) * 2007-12-13 2009-09-24 Scott Jenkins Nanoparticulate Anidulafungin Compositions and Methods for Making the Same
CN102176931B (en) 2008-08-09 2015-03-04 麻省理工学院 Implantable drug delivery device and methods of treating male genitourinary and surrounding tissues
KR20110130440A (en) * 2009-02-26 2011-12-05 바스프 에스이 Compositions, use and method for the use of surface active proteins in topical drug delivery across keratin
EA023156B1 (en) 2009-06-26 2016-04-29 ТАРИС Биомедикал ЛЛК Drug delivery device
US20110008469A1 (en) * 2009-07-09 2011-01-13 Florida Gulf Coast University Antimicrobial composition and methods and apparatus for use thereof
US9017312B2 (en) * 2009-09-10 2015-04-28 Taris Biomedical Llc Implantable device for controlled drug delivery
RU2479305C2 (en) * 2010-12-06 2013-04-20 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Pharmaceutical composition for treating infectious inflammatory diseases and method for preparing it
JP2014503554A (en) 2011-01-10 2014-02-13 タリス バイオメディカル，インコーポレイテッド Lidocaine regimen for the use of continuous treatment of bladder pain and irritating urination
CA2825399A1 (en) 2011-02-04 2012-08-09 Taris Biomedical, Inc. Implantable device for controlled release of low solubility drug
WO2012109363A2 (en) 2011-02-08 2012-08-16 The Johns Hopkins University Mucus penetrating gene carriers
ES2615236T3 (en) 2011-04-04 2017-06-06 Environ Skin Care (Pty) Ltd Treatment of viral infections
RU2013150323A (en) 2011-05-02 2015-06-10 Апталис Фарматек, Инк. COMPOSITIONS IN THE FORM OF QUICK DISPLACEMENT TABLETS FOR VAGINAL INTRODUCTION
JP6047576B2 (en) * 2011-09-19 2016-12-21 オムニアクティブ ヘルス テクノロジーズ リミテッド An efficient method for the preparation of edible lycopene-containing oleoresin and lycopene crystals
US9180094B2 (en) 2011-10-12 2015-11-10 The Texas A&M University System High porosity materials, scaffolds, and method of making
CN104936620B (en) * 2012-01-19 2019-08-09 约翰霍普金斯大学 Enhance the nanoparticle composite of transmucosal
CA2878680C (en) 2012-07-23 2019-09-17 Crayola, Llc Dissolvable films and methods of using the same
RU2538703C2 (en) * 2013-03-12 2015-01-10 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Pharmaceutical composition for treating vaginal candidiasis and method for preparing it
SG11201507294WA (en) 2013-03-15 2015-10-29 Taris Biomedical Llc Drug delivery devices with drug-permeable component and methods
JP6341200B2 (en) * 2013-05-30 2018-06-13 大正製薬株式会社 Suppository
KR102385603B1 (en) 2013-08-19 2022-04-11 타리스 바이오메디컬 엘엘씨 Multi-unit drug delivery devices and methods
US10363215B2 (en) 2013-11-08 2019-07-30 The Texas A&M University System Porous microparticles with high loading efficiencies
US20150238549A1 (en) * 2014-02-27 2015-08-27 Mak Wood, Inc. Probiotic dosage units
WO2015134500A1 (en) 2014-03-03 2015-09-11 Cook Medical Technologies Llc Mechanical dilator
US10335500B2 (en) 2014-05-12 2019-07-02 The Johns Hopkins University Highly stable biodegradable gene vector platforms for overcoming biological barriers
WO2016172704A1 (en) 2015-04-23 2016-10-27 Taris Biomedical Llc Drug delivery devices with drug-permeable component and methods
EP3302427A4 (en) 2015-05-29 2019-01-02 Eve Pharma Ltd. Ph-dependent vaginal compositions and methods of treatment of vaginal disorders
EP3355893A4 (en) 2015-09-29 2019-06-12 Kimberly-Clark Worldwide, Inc. Synergistic composition for maintenance of healthy balance of microflora
KR101880179B1 (en) * 2016-11-03 2018-07-20 한국생명공학연구원 Composition for treating antivirus containing micafungin or pharmaceutically acceptable salts thereof as an active ingredient
CN110799198A (en) * 2016-11-30 2020-02-14 普罗生物瑞士股份公司 Urogenital medical device formulation based on suitable biochemical compositions for stabilizing the acidity and redox state of vaginal fluids
CA3123051A1 (en) * 2018-12-19 2020-06-25 Healthy Cow Corporation Ready-to-use probiotic compositions and uses thereof
US11529346B2 (en) * 2020-06-18 2022-12-20 National Medical Supply, LLC Vaginal gel

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716637A (en) * 1993-05-18 1998-02-10 Pharmos Corporation Solid fat nanoemulsions as vaccine delivery vehicles

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3988508A (en) 1973-03-08 1976-10-26 Petrolite Corporation High internal phase ratio emulsion polymers
DE3321043A1 (en) * 1983-06-10 1984-12-13 Bayer Ag, 5090 Leverkusen ANTIMYCOTIC AGENTS FOR UNIQUE GYNAECOLOGICAL TREATMENT
US4551148A (en) 1982-09-07 1985-11-05 Kv Pharmaceutical Company Vaginal delivery systems and their methods of preparation and use
US5266329A (en) 1985-10-31 1993-11-30 Kv Pharmaceutical Company Vaginal delivery system
US5536743A (en) 1988-01-15 1996-07-16 Curatek Pharmaceuticals Limited Partnership Intravaginal treatment of vaginal infections with buffered metronidazole compositions
US4895452A (en) 1988-03-03 1990-01-23 Micro-Pak, Inc. Method and apparatus for producing lipid vesicles
US5055303A (en) 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
CA1337279C (en) 1989-06-06 1995-10-10 Robert J. Borgman Intravaginal treatment of vaginal infections with buffered metronidazole compositions
US5298246A (en) 1991-01-09 1994-03-29 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Stable pharmaceutical composition and method for its production
EP0535937B2 (en) 1991-10-01 2008-05-21 Takeda Chemical Industries, Ltd. Prolonged release microparticle preparation and production of the same
US5189070A (en) 1992-05-29 1993-02-23 Shell Oil Company Process for preparing low density porous crosslinked polymeric materials
US6191105B1 (en) 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
US5744155A (en) 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
US5470885A (en) 1993-09-29 1995-11-28 The Research Foundation Of The State University Of New York Fluorocarbons as anti-inflammatory agents
TW438601B (en) 1994-05-18 2001-06-07 Janssen Pharmaceutica Nv New mucoadhesive emulsion compositions and a process for the preparation thereof
US5980936A (en) 1997-08-07 1999-11-09 Alliance Pharmaceutical Corp. Multiple emulsions comprising a hydrophobic continuous phase
AU740758B2 (en) 1997-10-28 2001-11-15 Vivus, Inc. Treatment of female sexual dysfunction
US5877216A (en) 1997-10-28 1999-03-02 Vivus, Incorporated Treatment of female sexual dysfunction
US6899890B2 (en) * 2002-03-20 2005-05-31 Kv Pharmaceutical Company Bioadhesive drug delivery system

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716637A (en) * 1993-05-18 1998-02-10 Pharmos Corporation Solid fat nanoemulsions as vaccine delivery vehicles

Also Published As

Publication number Publication date
JP4462818B2 (en) 2010-05-12
WO2003079981A2 (en) 2003-10-02
BR0202767A (en) 2004-05-25
CN101045034A (en) 2007-10-03
FR2837389A1 (en) 2003-09-26
ZA200407535B (en) 2006-06-28
HUP0203102A2 (en) 2004-05-28
EP1494630A4 (en) 2007-03-14
AR039037A1 (en) 2005-02-02
PT102854B (en) 2004-02-27
AU2003218233A1 (en) 2003-10-08
CN102048689A (en) 2011-05-11
AU2002300175B2 (en) 2004-04-22
AU2003218233A8 (en) 2003-10-08
RU2004130870A (en) 2005-06-10
PT102854A (en) 2003-09-30
RU2320322C2 (en) 2008-03-27
HUP0203102A3 (en) 2004-06-28
EP1494630A2 (en) 2005-01-12
CN1444926A (en) 2003-10-01
CA2392473C (en) 2007-09-18
KR20030076159A (en) 2003-09-26
HU0203102D0 (en) 2002-11-28
US20030180366A1 (en) 2003-09-25
ITMI20021660A1 (en) 2004-01-26
KR20080098576A (en) 2008-11-11
JP2003286193A (en) 2003-10-07
AU2002300175A1 (en) 2003-10-09
US6899890B2 (en) 2005-05-31
CA2392473A1 (en) 2003-09-20
MXPA02006943A (en) 2004-12-13

Similar Documents

Publication Publication Date Title
WO2003079981A3 (en) Bioadhesive drug delivery system
CA2337046A1 (en) Sustained release pharmaceutical preparation
AU4681200A (en) A pharmaceutical composition of concentrates for microemulsion and self-emulsifying drug delivery system
AU2002216701A1 (en) Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
WO2004082588A3 (en) Dispersible formulation of an anti-inflammatory agent
WO2001095899A8 (en) Pharmaceutical compositions comprising cannabidiol derivatives
AR033548A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING A LIPASA INHIBITOR, A PROCEDURE FOR THEIR PREPARATION, TRANSPORTABLE EQUIPMENT IN A KIT MODE, THE USE OF SUCH COMPOSITION IN THE MANUFACTURE OF MEDICINES, A LIPASE INHIBITOR AND A BICYCLE SEQUOSTRANT
WO2001066093A3 (en) Sustained release ranolazine formulations
AU5325000A (en) Solubility enhancement of drugs in transdermal drug delivery systems and methodsof use
BR0314354A (en) Formation for lipophilic people
FR2761889B1 (en) PHARMACEUTICAL, COSMETIC OR DERMO-PHARMACEUTICAL PATCH FOR THE DELIVERY OF SEVERAL ACTIVE COMPOUNDS OF DIFFERENT NATURE
WO2006102446A3 (en) Multi-particulate, modified-released colonic composition
BG108516A (en) Pharmaceutical formulation
ID24818A (en) PHARMACEUTICAL COMPOSITION USED ON SLIMMING
AU2001280764A1 (en) Drug delivery system for enhanced bioavailability of hydrophobic active ingredients
WO2002048141A1 (en) Medicinal compositions improved in solublity in water
WO2004047792A3 (en) Liposomal glucocorticoids
AU2003238221A1 (en) Ibuprofen suspension
CA2332876A1 (en) Efavirenz compressed tablet formulation
CA2420461A1 (en) Preparations for oral administration
AU777185C (en) Pharmaceutical form of administration for peptides, methods for its production and use
CA2433833A1 (en) Use of flumazenil in developing a drug for the treatment of alcohol dependence
MXPA04005783A (en) Pharmaceutical formulation comprising cyclosporin and use thereof.
CA2285985A1 (en) A method for preparing aqueous liposomal compositions comprising an active ingredient which is highly insoluble in water
AU2001267561A1 (en) Combination preparations of 3-n-formylhydroxylaminopropyl phosphonic acid derivatives or 3-n-acetylhydroxylaminopropyl phosphonic acid derivatives combined withspecific pharmaceutical active agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2004/07535

Country of ref document: ZA

Ref document number: 200407535

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2003714226

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2004130870

Country of ref document: RU

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2003714226

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP